After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new assetnews2025-12-18T16:35:36+00:00December 18th, 2025|Endpoints News|
Biopharma’s winners and losers of 2025news2025-12-18T16:20:28+00:00December 18th, 2025|Endpoints News|
Takeda’s $4B immunology drug achieves first Phase 3 successesnews2025-12-18T15:58:06+00:00December 18th, 2025|Endpoints News|
Subcutaneous Rybrevant; Kalaris shares nAMD data; Pyxis disappointsnews2025-12-18T15:47:22+00:00December 18th, 2025|Endpoints News|
Alnylam, INCOG and Novartis expand in US; Ember gets $16.5M Series Anews2025-12-18T14:57:00+00:00December 18th, 2025|Endpoints News|
